Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia - Abdelnour, Carla; van Steenoven, Inger; Londos, Elisabet; Blanc, Frédéric; Auestad, Bjørn; Kramberger, Milica G.; Zetterberg, Henrik; Mollenhauer, Brit; Boada, Mercè; Aarsland, Dag (Movement disorders, 2016)
Keywords: a-beta; Aged; Aged, 80 and over; alpha-synuclein; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - physiopathology; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Biomarkers; bodies; Cerebrospinal fluid; Clinical Medicine; Cognitive ability; cognitive decline; csf amyloid-beta; CSF biomarkers; Dementia; Dementia disorders; differential-diagnosis; Disease Progression; Female; Follow-Up Studies; Humans; Klinisk medicin; Lewy bodies; Lewy body dementia; Lewy Body Disease - cerebrospinal fluid; Lewy Body Disease - physiopathology; Life Sciences; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Mental Status and Dementia Tests; mini-mental-state; Movement disorders; Neurodegenerative diseases; Neurologi; Neurology; Neurons and Cognition; Neurosciences; Neurosciences & Neurology; Neurovetenskaper; Parkinson's disease; parkinsons-disease; pathology; Peptide Fragments - cerebrospinal fluid; Prognosis; Tau protein; tau Proteins - cerebrospinal fluid; Threonine; Vitamin E; β-Amyloid; CSF biomarkers; cognitive decline; Lewy body dementia